UBS/CALL/ELI LILLY & CO/620/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 13:25:31 2024-06-28 EDT | ||
| 28.36 EUR | +2.27% |
|
| Current month | +43.59% | ||
| 1 month | +50.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 28.36 | +2.27% |
| 24-06-27 | 27.73 | +1.32% |
| 24-06-26 | 27.37 | -0.91% |
| 24-06-25 | 27.62 | +1.47% |
| 24-06-24 | 27.22 | +3.46% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 01:25 pm
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UL8JHD |
| ISIN | CH1294722439 |
| Date issued | 2023-09-07 |
| Strike | 620 $ |
| Maturity | 2024-09-20 (83 Days) |
| Parity | 10 : 1 |
| Emission price | 4.54 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 28.64 € |
|---|---|
| Lowest since issue | 3.51 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.460 |
| Difference Strike | -285.4 $ |
| Difference Strike % | -46.03% |
| Intrinsic value | 26.64 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
